Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Mar 20, 2026; 16(1): 113191
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.113191
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.113191
Advancing chronic low back pain management: Insights from amitriptyline and duloxetine comparison
Shree Rath, Department of Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar 751019, Odisha, India
Author contributions: Rath S was responsible for conceptualization, data curation, writing and review of the manuscript.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shree Rath, MD, Department of Medicine, All India Institute of Medical Sciences Bhubaneswar, Sijua, Patrapada, Bhubaneswar 751019, Odisha, India.
Received: August 19, 2025
Revised: September 14, 2025
Accepted: November 18, 2025
Published online: March 20, 2026
Processing time: 176 Days and 5.5 Hours
Revised: September 14, 2025
Accepted: November 18, 2025
Published online: March 20, 2026
Processing time: 176 Days and 5.5 Hours
Core Tip
Core Tip: This manuscript highlights the comparative effectiveness of amitriptyline and duloxetine for chronic low back pain (CLBP). While amitriptyline provides rapid early pain relief, duloxetine offers more durable reduction with fewer side effects, making it preferable for sustained management. The study’s real-world approach, using robust statistical adjustments and patient-centered outcomes, emphasizes the importance of personalized treatment strategies in chronic pain. These findings support duloxetine as a promising option and underscore the need for further randomized trials to refine evidence-based guidelines for CLBP management.